After operating its first factory located in Sentul, Bogor, PT Oneject Indonesia is ready to expand and inaugurate its second factory in Cikarang to meet the needs of increasing medical device production units.

With the second factory ready to be inaugurated in 2021, the company will receive an additional 900 million Auto Disable Syringes (ADS) and will become the largest ADS and Safety Needle producer in Asia with a total production capacity of 1.2 billion.

As time goes by, the ratio of injecting equipment use to the population in Indonesia tends to increase, and as a result, Oneject Indonesia’s second factory also supports the government’s program to expand the use of domestic products in the medical device segment by increasing government services in the health sector.

Not only producing medical devices in the form of syringes, but this second factory is also a production center for medical devices such as the Swab Antigen Test in collaboration with the principals of global medical device companies such as Abbott Laboratories and other medical device products.

The presence of the new Oneject Indonesia factory can ensure that the supply of syringes for the vaccination program in Indonesia will be met by Oneject syringe products that are recommended and have WHO (World Health Organization) standards and have a TKDN (Domestic Component Level) above 60% owned by Oneject.

PT Oneject Indonesia is committed to continue to innovate into a medical device industry that can always be used together. With this company, the people of Indonesia will always get support in terms of health for the sake of the sustainability of the welfare of the Indonesian state.